ET-02 is under clinical development by EdiGene and currently in Phase II for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase II drugs for B-Cell Non-Hodgkin Lymphoma have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ET-02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ET-02 overview

ET-02 is under development for the treatment of relapsed and refractory B-cell acute lymphocytic leukemia (ALL), B-cell non-Hodgkin lymphoma (NHL). It is a universal chimeric antigen receptor T cell therapy (U-CAR-T). The therapy is developed using CRISPR/Cas9 gene-editing platform technology.

EdiGene overview

EdiGene is a China-based biotechnology company. The company develops genome editing technologies for a range of diseases and provides creative solutions to advance drug discovery.

For a complete picture of ET-02’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.